Neos Therapeutics Inc Quick Ratio (NEOS) starting from the third quarter 2020 to third quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Neos Therapeutics Inc   (NASDAQ: NEOS)

Neos Therapeutics Inc 's Quick Ratio

NEOS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2020, Quick Ratio fell to 0.19 a new company low.

Within Major Pharmaceutical Preparations industry 365 other companies have achieved higher Quick Ratio than Neos Therapeutics Inc in third quarter 2020. While Quick Ratio total ranking in the third quarter 2020 has deteriorated compared to the prior quarter from 2638 to 3965.

Explain Quick Ratio?
How much Cash & cash equivalents NEOS´s has?
What are NEOS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NEOS Quick Ratio (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3
Y / Y Current Liabilities Change 51.28 % -0.46 % 1.7 % -17.98 % -16.97 %
Y / Y Cash & cash equivalent Change -49.58 % -58.09 % -20.31 % -46.44 % 52.68 %
Quick Ratio MRQ 0.19 0.32 0.61 0.53 0.57
NEOS's Total Ranking # 3965 # 2638 # 2085 # 1753 # 2761
Seq. Current Liabilities Change 67.67 % -23.2 % 11.36 % 5.5 % 10.33 %
Seq. Cash & cash equivalent Change 0.51 % -60.19 % 27.94 % -1.51 % -16.45 %



Quick Ratio third quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 366
Healthcare Sector # 890
Overall Market # 3965


Quick Ratio Statistics
High Average Low
7.77 2.14 0.19
(Sep 30 2015)   (Sep 30 2020)




Financial Statements
Neos Therapeutics Inc 's Current Liabilities $ 67 Millions Visit NEOS's Balance sheet
Neos Therapeutics Inc 's Cash & cash equivalent $ 13 Millions Visit NEOS's Balance sheet
Source of NEOS's Sales Visit NEOS's Sales by Geography


Cumulative Neos Therapeutics Inc 's Quick Ratio

NEOS's Quick Ratio for the trailling 12 Months

NEOS Quick Ratio

 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth 6.83 % -9.23 % -15.78 % -11.68 % -2.42 %
Y / Y Cash & cash equivalent TTM Growth -42.12 % -28.93 % -14.32 % -6.16 % 7.36 %
Quick Ratio TTM 0.4 0.52 0.61 0.66 0.74
Total Ranking TTM # 4912 # 4633 # 4623 # 4607 # 4524
Seq. Current Liabilities TTM Growth 12.41 % -0.1 % 0.48 % -5.32 % -4.49 %
Seq. Cash & cash equivalent TTM Growth -13.23 % -15.65 % -6.74 % -15.2 % 6.54 %

Quick ratio ranking by company, industry and sector >> Back to NEOS Financial Strength Comparisons >> Go to Compare NEOS Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2020 to $67.16 millions, cumulative Quick Ratio decreased to 0.4 below the Neos Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 491 other companies have achieved higher Quick Ratio than Neos Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2020 from 4633 to 4912.

Explain Quick Ratio?
How much Cash & cash equivalents NEOS´s has?
What are NEOS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 492
Healthcare Sector # 952
Within the Market # 4912


trailing twelve months Quick Ratio Statistics
High Average Low
5.48 1.8 0.32
(Jun 30 2016)   (Sep 30 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2020, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2020 MRQ Cash & cash equivalentSep 30 2020 MRQ Current Liabilities
Lannett Company Inc  0.50 $ 108.774  Millions$ 219.204  Millions
Mannkind Corporation  0.49 $ 52.398  Millions$ 106.124  Millions
Cv Sciences Inc   0.47 $ 5.563  Millions$ 11.827  Millions
Abbott Laboratories  0.46 $ 4,731.000  Millions$ 10,257.000  Millions
Grifols Sa  0.43 $ 649.205  Millions$ 1,495.355  Millions
Amneal Pharmaceuticals Inc   0.42 $ 283.650  Millions$ 667.886  Millions
Bausch Health Companies Inc   0.42 $ 977.000  Millions$ 2,327.000  Millions
Regenerx Biopharmaceuticals inc   0.40 $ 0.139  Millions$ 0.345  Millions
Morphosys Ag  0.40 $ 122.970  Millions$ 305.965  Millions
The Greater Cannabis Company Inc   0.37 $ 0.179  Millions$ 0.481  Millions
Merck and Co Inc   0.36 $ 7,356.000  Millions$ 20,405.000  Millions
Redhill Biopharma Ltd   0.36 $ 29.295  Millions$ 81.386  Millions
Elanco Animal Health Incorporated  0.35 $ 659.900  Millions$ 1,871.200  Millions
Aridis Pharmaceuticals Inc   0.34 $ 6.212  Millions$ 18.120  Millions
Nexien Biopharma Inc   0.33 $ 0.008  Millions$ 0.025  Millions
Abbvie Inc   0.33 $ 7,950.000  Millions$ 24,181.000  Millions
Intelgenx Technologies Corp   0.33 $ 1.531  Millions$ 4.667  Millions
Novartis Ag  0.30 $ 9,897.000  Millions$ 33,059.000  Millions
Vtv Therapeutics Inc   0.28 $ 2.358  Millions$ 8.296  Millions
Rapid Therapeutic Science Laboratories Inc   0.27 $ 0.266  Millions$ 0.981  Millions
International Stem Cell Corporation  0.27 $ 1.026  Millions$ 3.852  Millions
Assertio Holdings inc   0.26 $ 34.737  Millions$ 131.374  Millions
Avricore Health Inc   0.26 $ 0.237  Millions$ 0.905  Millions
Cytodyn inc   0.24 $ 18.200  Millions$ 76.424  Millions
Ani Pharmaceuticals Inc  0.24 $ 17.900  Millions$ 75.900  Millions
Serina Therapeutics Inc   0.23 $ 1.107  Millions$ 4.854  Millions
Medicure Inc   0.22 $ 2.080  Millions$ 9.430  Millions
Iterum Therapeutics Plc  0.21 $ 8.570  Millions$ 40.792  Millions
Emmaus Life Sciences Inc   0.21 $ 4.949  Millions$ 23.780  Millions
Enveric Biosciences Inc   0.20 $ 2.840  Millions$ 13.993  Millions

Date modified: 2026-09-08T15:10:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.